Publications

Yasuhiro Shudo, MD, PhD
Clinical Associate Professor, Cardiothoracic Surgery

Publications

  • Ex Vivo Heart Perfusion Offsets Ischemic Penalties with ≥6-Hour Preservation in Adult Donation-After-Brain-Death Heart Transplantation. The Journal of thoracic and cardiovascular surgery Berg, A. R., Krishnan, A., Heng, E. E., Choi, A. Y., Zhou, A., Alnasir, D. I., Ruaengsri, Y. C., Shudo, Y., Woo, Y. J., MacArthur, J. W. 2025

    Abstract

    The 2018 UNOS allocation revision broadened sharing and lengthened preservation. Survival declines after four hours of cold ischemia, with sharper losses beyond six. Ex vivo heart perfusion (EVHP) may mitigate this risk, but real-world effectiveness in the United States is uncertain.We analyzed adult heart transplants in UNOS (January 1st, 2019- April 1st, 2025). We studied DBD hearts with preservation ≥6 hours, comparing EVHP with a No-EVHP group (pooled static and hypothermic cold storage). The primary outcome was one-year mortality; secondary outcomes were 90-day and three-year mortality, postoperative complications, and cause of death. Analyses included Kaplan-Meier estimates, Cox regression, restricted cubic splines, and 1:1 propensity matching.Of 16,859 DBD recipients, 546 had preservation ≥6 hours (EVHP n=320; No EVHP group n=226). One-year survival was higher with EVHP (92.5% vs 86.3%, p=0.029) and at three years (90.9% vs 79.6%, p<0.001). In adjusted models, the No EVHP ≥6 hours group had greater one-year mortality than EVHP ≥6 hours (hazard ratio 1.90, 95% CI 1.08-3.35, p=0.027). In a four-level model, EVHP ≥6 hours had outcomes comparable to EVHP <6 hours and the No EVHP <6 hours group, with excess risk confined to the No EVHP ≥6 hours group. Splines showed rising mortality with longer preservation in the No EVHP group and attenuation with EVHP. Postoperative complications and cause of death were similar. Benefits concentrated at higher-volume centers.In contemporary U.S. practice, EVHP was associated with improved survival for ≥6-hour preservation, particularly at high-volume programs, mitigating the survival penalty from prolonged preservation.

    View details for DOI 10.1016/j.jtcvs.2025.11.025

    View details for PubMedID 41360280

  • Invited Response Letter. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Berg, A. R., Krishnan, A., Heng, E. E., Choi, A. Y., Garrison, A. C., Alnasir, D. I., Chawannuch Ruaengsri, Y., Shudo, Y., Joseph Woo, Y., MacArthur, J. W. 2025

    View details for DOI 10.1016/j.healun.2025.11.025

    View details for PubMedID 41349593

  • Ex-vivo Heart Perfusion Attenuates Early Post-Transplant Risk After Prolonged Agonal Period in DCD Heart Transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Berg, A. R., Krishnan, A., Heng, E. E., Choi, A. Y., Garrison, A. C., Alnasir, D. I., Chawannuch Ruaengsri, Y., Shudo, Y., Joseph Woo, Y., MacArthur, J. W. 2025

    Abstract

    Warm ischemic injury during the agonal period (AP) threatens graft viability in donation-after-circulatory-death (DCD) heart transplantation. Whether ex-vivo heart perfusion (EVHP) mitigates these risks remains unclear. ex-vivo METHODS: Adult (≥ 18 y) isolated heart transplants reported to the UNOS thoracic registry (January 2019-April 2025) were reviewed. Recipients lacking AP or perfusion data were excluded. The primary exposure was EVHP, defined as use of an ex-vivo perfusion device following donor cardiectomy; static cold storage served as the reference. Multivariable Cox and logistic models adjusted for donor, recipient, procedural, and center-level factors. Propensity score matching was performed in the prolonged AP subgroup.Among 1,682 DCD recipients, 1,175 (69.9%) received EVHP. Prolonged AP (≥30 min) occurred in 359 cases. One-year survival was 90.7% overall. In the fully adjusted Cox model, no-EVHP grafts with AP ≥30 min had higher 1-year mortality versus the reference (no-EVHP + <30 min) (HR 2.17; 95% CI 1.05-4.47; p=0.037). EVHP grafts showed no excess risk regardless of AP (EVHP + <30 min: HR 0.93; 95% CI 0.54-1.62; p=0.809; EVHP + ≥30 min: HR 0.98; 95% CI 0.49-1.96; p=0.953). Age, creatinine, out-of-body time, and ACHD increased mortality; VAD at listing and high-volume centers were protective; sex was not significant. In the AP ≥30-min PSM subgroup (n=240; 120 EVHP, 120 no EVHP), EVHP improved 1-year survival (log-rank p=0.03). Spline modeling showed rising mortality beginning ~20 minutes of AP for static-preserved grafts, with a flat risk curve under EVHP. Static-preserved prolonged-AP grafts had higher odds of acute rejection before discharge (aOR 2.56; 95% CI 1.07-6.14; p=0.04); stroke, dialysis, and pacemaker use did not differ.EVHP may mitigate survival and rejection penalties of prolonged AP in U.S. DCD heart transplantation. Broader EVHP adoption for donors with AP ≥ 30 min may safely expand the DCD heart pool without compromising outcomes.

    View details for DOI 10.1016/j.healun.2025.10.012

    View details for PubMedID 41241031

  • 7Improved 2-year Heart Transplant Survival with Moderate Hypothermic Donor Heart Preservation in the GUARDIAN Heart Registry. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation Silvestry, S., Meyer, D. M., Pham, S. M., Jacobs, J. P., Shudo, Y., Schroder, J., Leacche, M., Sciortino, C. M., Rodrigo, M. E., Takeda, K., Couper, G., Kawabori, M., Mahesh, B., Klein, L., Vidic, A., Patel, S. R., Loyaga-Rendon, R., Urban, M., D'Alessandro, D. A. 2025

    Abstract

    Multiple advanced preservation technologies are now available and have demonstrated utility in organ assessment and preservation. The Paragonix SherpaPak® Cardiac Transport System (SCTS) has become the most common method of static preservation demonstrating superior outcomes to historic ice storage. To date, no preservation method has reported improved post-transplant survival.Data from the GUARDIAN-Heart Registry, the largest real-world registry focused on organ preservation, were analyzed to quantify post-transplant clinical outcomes and survival in transplant cases utilizing ice cooler storage or moderate hypothermic preservation using SCTS. The independent contributions of organ preservation method on outcomes, including severe primary graft dysfunction (PGD), right ventricular dysfunction (RVD), and mortality, were analyzed using propensity matching and logistic regression.Among 1,261 US adult heart transplants performed between October 2015 - January 2024, SCTS utilization was associated with significant reductions in incidence of severe PGD (Ice 10.8% vs. SCTS 6.8%, p=0.015) and severe RVD (Ice 9.9% vs. SCTS 6.1%, p=0.022). SCTS use was identified as an independent predictor of severe PGD (Odds Ratio = 0.60, p=0.012) and severe RVD (OR = 0.75, p=0.047). In the propensity-matched cohort, SCTS utilization was associated with a significant reduction in mortality after 2 years (Ice 10.5% vs. SCTS 5.7%, p=0.042), and the Kaplan-Meier survival probability over 2 years was significantly higher in the SCTS cohort (p=0.022).Moderate, controlled hypothermic preservation using SCTS significantly improves post-transplant outcomes and 2-year survival. This is the first study of any advanced heart preservation modality to demonstrate a significant impact on transplant survival.

    View details for DOI 10.1016/j.healun.2025.10.002

    View details for PubMedID 41241029

  • Dual Contrast-Enhanced Microcomputed Tomography Uncovers Leaflet-Dependent Patterns of Macrocalcification, Fibrous Extracellular Matrix Remodeling, and Adipocyte Degeneration in Calcific Aortic Stenosis. Journal of the American Heart Association El Zeini, M., Tacco, I. R., Jimenez, J. I., Kabiri, A., Vailionis, A., Perrino, J., Burns, D., Jensen, K. C., Burdon, T. A., Shudo, Y., Woo, Y. J., Liang, T., Alexander, K. M., Joubert, L. M., Chen, I. Y. 2025: e040616

    Abstract

    Clinical imaging studies of calcific aortic stenosis have suggested interleaflet pathological differences in patients. In this cross-sectional study, we sought to investigate interleaflet differences in calcification, fibrous extracellular matrix remodeling, and adipocyte degeneration in explanted human aortic valves.Diseased (n=45) and control (n=39) tricuspid aortic valve leaflets obtained from patients with aortic stenosis and normal aortic valves on echocardiography were assessed for calcification, fibrous extracellular matrix remodeling, and adipocyte degeneration using contrast-enhanced microcomputed tomography in conjunction with scanning and transmission electron microscopy, with interleaflet differences analyzed by fractional response regression.In diseased leaflets, the calcification volume fraction was significantly greater in the noncoronary cusp than the left coronary cusp (LCC; β=0.313 [95% CI, 0.048-0.579], P=0.021) but not than the right coronary cusp (RCC; β=0.196 [95% CI, -0.107 to 0.499], P=0.204), with no difference between the RCC and LCC (β=0.117 [95% CI, -0.150 to 0.385], P=0.390). However, the fibrous extracellular matrix volume fraction was significantly greater in the RCC and LCC than the noncoronary cusp (β=0.502 [95% CI, 0.300-0.704], P<0.001; β=0.388 [95% CI, 0.188-0.589], P<0.001), with the RCC also greater than the LCC (β=0.114 [95% CI, 0.065-0.163], P<0.001). The volume fraction of osmium-labeled inclusions observed on microcomputed tomography-confirmed to be predominantly adipocytes (95.4 [IQR, 72.4-99.0]%) and occasionally membranous fat necrosis (4.6 [IQR, 1.0-27.6]%) on electron microscopy-was significantly less in the noncoronary cusp than the LCC (β=-0.269 [95% CI, -0.441 to -0.096], P=0.002) but not than the RCC (β=-0.185 [95% CI, -0.409 to 0.038], P=0.104), with no difference between the RCC and LCC (β=-0.083 [95% CI, -0.348 to 0.182], P=0.538).Valvular calcification diverges from fibrous extracellular matrix remodeling but converges with adipocyte degeneration in terms of preferential impact on the noncoronary cusp versus, in particular, the LCC. Future mechanistic studies to elucidate the intimate relationship between adipocyte degeneration and valvular calcification may provide opportunities for further therapeutic development.

    View details for DOI 10.1161/JAHA.124.040616

    View details for PubMedID 41182010

  • Simultaneous heart-kidney transplantation outcomes in Asian populations in the United States: A united network for organ sharing database study. JHLT open Yajima, S., He, H., Elde, S., Zhu, Y., Woo, Y. J., Shudo, Y. 2025; 10: 100364

    Abstract

    Simultaneous heart-kidney transplantation (HKTx) remains underutilized in regions outside the United States and Europe. Assessing the clinical outcomes of HKTx in Asian recipients is crucial for promoting its adoption in Asia. This retrospective study aimed to compare the survival outcomes of HKTx between Asian and non-Hispanic White (NHW) recipients with similar baseline characteristics.This study included 1494 recipients aged ≥18 years who underwent HKTx for the first time between 2000 and 2022. Among them, 1392 were NHW and 102 were Asian. Propensity score matching was used to balance the baseline characteristics between the Asian and NHW recipients. Kaplan-Meier survival analysis and log-rank tests were utilized to evaluate and compare overall survival.In the prematched cohort, the in-hospital mortality rates were 10.0% and 6.7% for Asian and NHW recipients, respectively (p=0.216). Kaplan-Meier mortality estimates at 1, 5, and 10 years were 17.3%, 42.2%, and 67.7% for Asians, and 14.6%, 35.5%, and 65.9% for NHW recipients (p=0.692), respectively. After matching, the in-hospital mortality rates were 10.0% for Asians and 6.6% for NHW recipients (p=0.355). Long-term 1-, 5-, and 10-year mortality rates remained comparable: 13.9%, 36.1%, and 62.5% for Asians, versus 10.7%, 34.3%, and 59.2% for NHW recipients, respectively (p=0.665).Asian recipients demonstrated comparable long-term survival to NHW recipients after HKTx.

    View details for DOI 10.1016/j.jhlto.2025.100364

    View details for PubMedID 40893630

    View details for PubMedCentralID PMC12396451

  • Rapid manufacturing of angiogenic cellular collagen patches for ischemic cardiomyopathy. Stem cells translational medicine Pfrender, E., Kim, S., Farag, J. A., Yajima, S., Kawai, Y., Kawago, K., Syed, U., Ikeda, G., Ueyama, T., Takashima, H., Dalal, A., Zhu, Y., Ichimura, K., Liu, Y., Moeinzadeh, S., Koltsov, J., Wu, J. C., Woo, Y. J., Yang, P. C., Yang, Y. P., Shudo, Y. 2025; 14 (9)

    Abstract

    One in ten Americans carry a lifetime risk of ischemic heart failure, the most severe form of ischemic heart disease. Carrying a nearly 50% five‑year mortality rate, no interventional therapy exists to treat the underlying cause, microvascular malperfusion. In efforts to combat microvascular malperfusion, our group has utilized synergistic application of endothelial progenitor cells (EPCs) and smooth muscle cells (SMCs) to induce angiogenesis in ischemic myocardium.Cells are then embedded into a rapidly manufacturable compressed collagen (CC) patch to provide a biosimilar scaffold ready for transplantation. The performance of the cellular compressed collagen patch was then tested on a rodent acute myocardial infarction model of ischemic heart failure.By post‑transplantation Day 28, the cellular CC patch improved left ventricular ejection fraction when compared to an acellular CC patch and control (cellular: 49.1 ± 1.8%; acellular: 38.0 ± 2.6%; control: 39.2 ± 2.1%; ANOVA P = .0006). Cellular CC patch transplantation also induced mature angiogenesis as shown by arteriolar density (cellular: 1084 ± 98 αSMA+vWF+/mm2; acellular: 338 ± 57 αSMA+vWF+/mm2; control: 449 ± 39 αSMA+vWF+/mm2; ANOVA P = .0003) and vascular maturation index (cellular: 0.67 ± 0.04; acellular: 0.48 ± 0.02; and control: 0.46 ± 0.04, P = .001).In conclusion, transplantation of a rapidly manufacturable EPC‑SMC‑based compressed collagen patch effectively rescues myocardial function by enhancing neovascularization and attenuating post‑infarction myocardial injury.

    View details for DOI 10.1093/stcltm/szaf035

    View details for PubMedID 40973918

    View details for PubMedCentralID PMC12449208

  • Safety and 1-Year Outcomes After Transplanting Hearts From SARS-CoV-2 Positive Donors: Insights From an International Analysis. Immunity, inflammation and disease Guenther, S. P., Wadewitz, J., Wayda, B. J., Fox, H., Cheaban, R., Shudo, Y., Hiesinger, W., Costard-Jäckle, A., Morshuis, M., Woo, Y. J., Teuteberg, J. J., Schramm, R., Rahmel, A., Gummert, J. F., Khush, K. K. 2025; 13 (9): e70252

    Abstract

    Uncertainties persist regarding the utilization of hearts from SARS-CoV-2-positive donors for heart transplant (HT). This international study analyzed such HTs within the United States (US) and Germany, focusing on 1-year outcomes and granular safety data.Data was obtained from the United Network for Organ Sharing (UNOS) registry (03/2021-08/2022) and collaborating with the German Organ Procurement Organisation (DSO; 03/2022-02/2023). HTs from currently and recently (up to 21 days in UNOS and 90 days in DSO) SARS-CoV-2-positive donors were included.In the US, 274 HTs from SARS-CoV-2 donors were analyzed (50.7% SARS-CoV-2-positive until organ recovery). Compared to 3952 HTs from SARS-CoV-2-negative donors, acute rejection was less frequent (10.6% vs. 17.1%, p = 0.006). One-year graft and recipient survival (p = 0.327) and rehospitalization rates (p = 0.592) did not differ. In Germany, 30 HTs utilized SARS-CoV-2-positive hearts. Follow-up was obtained for 23 (76.7%). 43.5% of the donors were positive until recovery. Two recipients (8.7%) tested positive for SARS-CoV-2 21 and 65 days post-transplant, both unlikely donor-derived. 8.7% had severe PGD, 8.7% acute cellular rejection ≥ 2R. One-year survival was 91.3%. None experienced myocarditis or thromboembolism.Using selected SARS-CoV-2-positive hearts for transplant appears safe with no differences in 1-year survival, no evidence of viral transmission or SARS-CoV-2-related adverse cardiovascular events.

    View details for DOI 10.1002/iid3.70252

    View details for PubMedID 40911444

  • Does Preservation Strategy Modify Sex-Specific Risk of Severe Primary Graft Dysfunction After Heart Transplantation: A GUARDIAN-Heart Analysis Defilippis, E. M., Rodrigo, M., Loyaga-Rendon, R. Y., Shudo, Y., D'Alessandro, D., Fiedler, A. ELSEVIER SCIENCE INC. 2025

    View details for Web of Science ID 001552498800130

  • Over 1,000 Heart Transplants Using Donation After Circulator Death (DCD) Donors: Real-World Experience with the Organ Care System (OCS) Heart Shudo, Y., D'Alessandro, D. A., Anyanwu, A., Patel, P., Sareyyupo-glu, B., Takeda, K., Couper, G. S., Skipper, E., Esmailian, F., Peltz, M., Anwer, M., Pham, D., Pretorius, V., Kai, M., Villavicencio, M., Pal, J., Sun, B., Meyer, D., Daneshmand, M. A., Chan, J. L., Lozonschi, L., Selzman, C., Shah, A. S., Itoh, A., Kilic, A., Loebe, M., Ohira, S., Funamoto, M., Goldstein, D., Dowling, R., Klein, L., Haft, J., Durham, L., Salerno, C., Kaczorowski, D., Shaffer, A., Sulemanjee, N., Stehlik, J., Pinney, S., Farr, M., Milano, C., Schroder, J. N. ELSEVIER SCIENCE INC. 2025

    View details for Web of Science ID 001552499300012

  • Corrigendum to Ex vivo lung perfusion of pediatric lungs for adult recipients [JTCVS Techniques, Volume 29, 2025]. JTCVS techniques Krishnan, A., Fawad, M. M., Elde, S., Shah, V. K., Shudo, Y., Dhillon, G., MacArthur, J. W., Ruaengsri, C., Woo, Y. J., Guenthart, B. A. 2025; 32: 229

    Abstract

    [This corrects the article DOI: 10.1016/j.xjtc.2024.10.021.].

    View details for DOI 10.1016/j.xjtc.2025.05.013

    View details for PubMedID 40814691

    View details for PubMedCentralID PMC12347675

  • Sex Differences in Risk for Severe Primary Graft Dysfunction After Heart Transplantation: A GUARDIAN-Heart Analysis DeFilippis, E. M., Rodrigo, M., Loyaga-Rendon, R. Y., Shudo, Y., D'Alessandro, D., Fiedler, A. ELSEVIER SCIENCE INC. 2025

    View details for Web of Science ID 001552498800134

  • Heart Transplantation from Donation After Circulatory Death Donors: Comparison of the OCS Heart and Non-OCS Methods D'Alessandro, D., Schroder, J., Shudo, Y., Patel, P., Sareyyupoglu, B., Takeda, K., Couper, G., Skipper, E., Esmailian, F., Peltz, M., Anwer, M., Pham, D., Pretorius, V., Michel, E., Kai, M., Villavicencio, M., Pal, J., Sun, B., Meyer, D., Daneshmand, M. A., Chan, J. L., Lozonschi, L., Selzman, C., Shah, A. S., Itoh, A., Kilic, A., Loebe, M., Ohira, S., Funamoto, M., Goldstein, D., Dowling, R., Klein, L., Haft, J., Durham, L., Salerno, C., Kaczorowski, D., Shaffer, A., Sulemanjee, N., Stehlik, J., Pinney, S., Farr, M., Milano, C., Anyanwu, A. ELSEVIER SCIENCE INC. 2025

    View details for Web of Science ID 001552499300011

  • Comprehensive Analysis of Myocardial Reverse Remodeling Following HeartWare Ventricular Assist Device Implantation CLINICAL TRANSPLANTATION Kawai, Y., Farag, J. A., Nishiga, M., Liu, Y., Kawago, K., Koyano, T. K., Fong, R., Bilbao, M., Hiesinger, W., Shin, H., Pfrender, E. M., Dalal, A., Pedroza, A. J., Boyd, J. H., Woo, Y., Shudo, Y. 2025; 39 (8)

    View details for DOI 10.1111/ctr.70245

    View details for Web of Science ID 001537569900001

  • Which Donor and Recipient Risk Factors Matter in Heart Transplantation? Results From a Survey of 53 Centers Across Five Countries. Clinical transplantation Guenther, S. P., Schramm, R., Teuteberg, J. J., Shudo, Y., Rogge, A. L., Schaeper, K. E., Fox, H., Hoepner, L., Ruaengsri, C., Costard-Jaeckle, A., Hiesinger, W., Woo, Y. J., Morshuis, M., Khush, K. K., Gummert, J. F., Wayda, B. J. 2025; 39 (6): e70214

    Abstract

    Consensus regarding what defines acceptable heart transplant (HT) donors or recipients is lacking. This survey analyzed how risk factors guide donor and recipient selection, and how practices vary across systems.An online survey was conducted among adult HT centers in the US and Eurotransplant (ET) region. We aimed to represent at least 50% of the total adult HT volumes in both regions. Centers were stratified by their HT volumes. To compensate for non-responders, a safety margin was included, and centers accounting for at least 75% of the total HT volumes were contacted. Centers were queried on relative thresholds and absolute cutoffs for continuous risk factors. For other factors, their influence on donor heart acceptance or the likelihood of listing recipients was assessed.Fifty-three centers from five countries participated: 39 US (accounting for 51.0% of the US HT volume), and 14 ET centers (65.0%) from four countries. ET centers more liberally considered advanced age donor hearts (threshold 64.5 [60.0-70.0] vs. 50.0 [50.0-55.0] years, p < 0.001), and hearts with abnormal echocardiography or coronary findings. Diabetes, smoking, and hypertension were rated by a quarter to more than half of US and ET centers as moderately or heavily influencing donor heart acceptance. ET centers more liberally listed candidates with chronic kidney disease (GFR 30.0 [21.5-32.5] vs. 35.0 [30.0-40.0] mL/min/1.73m2, p < 0.001). US centers, conversely, allowed for higher candidate ages (71.5 [70.0-74.0] vs. 68.0 [65.0-70.0] years, p < 0.001), and more likely (76.9%) listed candidates on ECMO support (42.9% of ET centers to less likely list, p = 0.022).Selection practices differed distinctly between the US and ET. Further, practices appear to be driven by caution and are more conservative than current guidelines. Strengthening the evidence base to objectify and optimize donor and candidate selection could help alleviate the unmet need for donor hearts.

    View details for DOI 10.1111/ctr.70214

    View details for PubMedID 40536071

  • Beating Heart Transplant Technique in Donation After Circulatory Death (DCD) Heart Transplantation: A Propensity Matched Analysis of the National Transplant Registry Choi, A. Y., Kapula, N., He, H., Krishnan, A., Ruaengsri, C., Henricksen, E., Elde, S., Fawad, M., Teuteberg, J., Khush, K., Luikart, H., Shudo, Y., MacArthur, J. W., Hiesinger, W., Woo, J., Guenthart, B. A. ELSEVIER SCIENCE INC. 2025

    View details for Web of Science ID 001492184800072

  • Multiorgan Transplantation for Adult Congenital Heart Disease Heng, E. E., Krishnan, A., Elde, S., Fawad, M., Mullis, D., Aranda-Michel, E., Shou, B., Alnasir, D., Garrison, A., Ruaengsri, C., Shudo, Y., Guenthart, B., Woo, J., MacArthur, J. W. ELSEVIER SCIENCE INC. 2025

    View details for Web of Science ID 001492172200035

  • Global Outcomes with Extended Criteria Donors When Preserved at 4-8°C: An Updated Analysis of the International GUARDIAN Heart Registry Moayedifar, R., Esteve, A., Shudo, Y., Kawabori, M., Venkateswaran, R., Silvestry, S., Schroder, J., Maechler, H., Meyer, D., Bustamante-Munguira, J., D'Alessandro, D., Zuckermann, A. ELSEVIER SCIENCE INC. 2025

    View details for Web of Science ID 001492184800070

  • Extended Criteria Donor Hearts Are Associated with Higher Mortality Compared to Circulatory Death Donor Hearts Krishnan, A., Heng, E., Fawad, M., Choi, A., Elde, S., Shou, B., Aranda-Michel, E., Garrison, A., Alnasir, D., Berg, A. R., Ruaengsri, C., Shudo, Y., Guenthart, B., Woo, J., MacArthur, J. ELSEVIER SCIENCE INC. 2025

    View details for Web of Science ID 001509032000107

  • Impact of Final Cardioplegia Flush, Del Nido vs Histidine-TryptophanKetoglutarate Solution on OCS Heart Transplant Outcomes: Analysis of OCS Heart Perfusion Registry Ohira, S., D'Alessandro, D., Villavicencio, M., Gruber, P., Daneshmand, M., Shudo, Y., Goldstein, D., Pham, S., Couper, G., Klein, L., Shah, A., Lozonschi, L., Esmailian, F., Meyer, D., Takeda, K., Sun, B., Haft, J., Pham, D., Rajasekhar, M., Funamoto, M., Kaczorowski, D., Durham, L., Shaffer, A., Itoh, A., Schroder, J. ELSEVIER SCIENCE INC. 2025

    View details for Web of Science ID 001509032000081